Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Prognosis of gastrointestinal stromal tumors.

Bertin M, Angriman I, Scarpa M, Mencarelli R, Ranzato R, Ruffolo C, Polese L, Iacobone M, D'Amico DF.

Hepatogastroenterology. 2007 Jan-Feb;54(73):124-8.

PMID:
17419245
2.

Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.

Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY.

Chin Med J (Engl). 2010 Jan 20;123(2):131-6.

PMID:
20137358
3.

Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases.

Koay MH, Goh YW, Iacopetta B, Grieu F, Segal A, Sterrett GF, Platten M, Spagnolo DV.

Pathology. 2005 Feb;37(1):22-31.

PMID:
15875730
4.

Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.

Miettinen M, Sobin LH, Lasota J.

Am J Surg Pathol. 2009 Sep;33(9):1267-75. doi: 10.1097/PAS.0b013e3181a13e99.

PMID:
19440146
5.

Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.

Lee HE, Kim MA, Lee HS, Lee BL, Kim WH.

J Clin Pathol. 2008 Jun;61(6):722-9. doi: 10.1136/jcp.2007.052225. Epub 2008 Apr 1.

PMID:
18381383
6.

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).

Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W.

J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. Epub 2007 Apr 26.

PMID:
17458563
7.

Clinicopathologic features, cellular differentiation, PCNA and P53 expressions in gastrointestinal stromal tumors.

Can B, Sökmensüer C.

Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccxliii-ccxlviii.

PMID:
15244191
8.

Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.

Chirieac LR, Trent JC, Steinert DM, Choi H, Yang Y, Zhang J, Patel SR, Benjamin RS, Raymond AK.

Cancer. 2006 Nov 1;107(9):2237-44.

9.

Survival and prognostic factors analysis in surgically resected gastrointestinal stromal tumor patients.

Song Z, Wang JL, Pan YL, Tao DY, Gan MF, Huang KE.

Hepatogastroenterology. 2009 Jan-Feb;56(89):149-53.

PMID:
19453047
10.

A study of histopathological assessment criteria for assessing malignancy of gastrointestinal stromal tumor, from a clinical standpoint.

Yokoi K, Tanaka N, Shoji K, Ishikawa N, Seya T, Horiba K, Kanazawa Y, Yamashita K, Ohaki Y, Tajiri T.

J Gastroenterol. 2005 May;40(5):467-73.

PMID:
15942711
11.

Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.

Hou YY, Grabellus F, Weber F, Zhou Y, Tan YS, Li J, Shen KT, Qin J, Sun YH, Qin XY, Bockhorn M, Gerken G, Broelsch CE, Frilling A.

J Gastrointest Surg. 2009 Sep;13(9):1583-92. doi: 10.1007/s11605-009-0842-6. Epub 2009 Mar 17.

PMID:
19291337
12.
13.

Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors.

Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, Ni C, Wang X, Liu Y, Zhang L.

Hum Pathol. 2008 Mar;39(3):444-51. doi: 10.1016/j.humpath.2007.07.018.

PMID:
18261629
14.

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR.

Cancer. 2008 Feb 1;112(3):608-15.

15.

[Roles of risk assessment and Ki-67 index in judging prognostic of gastrointestinal stromal tumors].

Liang YM, Li XH, Chen W.

Zhonghua Yi Xue Za Zhi. 2008 Apr 15;88(15):1041-5. Chinese.

PMID:
18754437
16.

Histopathological features and clinical course of the gastrointestinal stromal tumors.

Di Matteo G, Pescarmona E, Peparini N, Di Matteo FM, Zeri KP, Mascagni D, Mele R, Maturo A, Redler A, De Antoni E.

Hepatogastroenterology. 2002 Jul-Aug;49(46):1013-6.

PMID:
12143190
17.

Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.

Hassan I, You YN, Shyyan R, Dozois EJ, Smyrk TC, Okuno SH, Schleck CD, Hodge DO, Donohue JH.

Ann Surg Oncol. 2008 Jan;15(1):52-9. Epub 2007 Nov 14.

PMID:
18000711
18.

Elevated p21 expression is associated with poor prognosis of rectal stromal tumors after resection.

Hu TH, Tai MH, Chuah SK, Chen HH, Lin JW, Huang HY, Chou YP, Yi LN, Kuo CM, Changchien CS.

J Surg Oncol. 2008 Aug 1;98(2):117-23. doi: 10.1002/jso.21094.

PMID:
18521824
19.

Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.

Zheng S, Chen LR, Wang HJ, Chen SZ.

Hepatogastroenterology. 2007 Dec;54(80):2285-90.

PMID:
18265649
20.

[Analysis of clinicopathology and prognosis in 181 patients with gastrointestinal stromal tumors].

Zhang Y, Cao H, Wang M, Shen DP, Shen ZY, Ni XZ, Wu ZY, Shen YY, Liu Q.

Zhonghua Wei Chang Wai Ke Za Zhi. 2009 Mar;12(2):150-4. Chinese.

PMID:
19296250

Supplemental Content

Support Center